China Isotope & Radiation's revenue for the
six
months ended in Dec. 2023 was HK$4,260 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$7,257 Mil.
China Isotope & Radiation's Revenue per Share for the
six
months ended in Dec. 2023 was HK$13.32.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$22.69.
Warning Sign:
China Isotope & Radiation Corp revenue growth has slowed down over the past 12 months.
During the past 9 years, China Isotope & Radiation's highest 3-Year average Revenue per Share Growth Rate was 18.80% per year. The lowest was 6.30% per year. And the median was 14.95% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of China Isotope & Radiation's Revenue
For the Medical Devices subindustry, China Isotope & Radiation's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation's Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Revenue distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's Revenue falls into.
China Isotope & Radiation Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$7,257 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation (HKSE:01763) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
China Isotope & Radiation Revenue Related Terms
Thank you for viewing the detailed overview of China Isotope & Radiation's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
China Isotope & Radiation (HKSE:01763) Business Description
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01763 has been successfully added to your 